<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="859">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 27, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01184417</url>
  </required_header>
  <id_info>
    <org_study_id>AlamedaCountyMC</org_study_id>
    <nct_id>NCT01184417</nct_id>
  </id_info>
  <brief_title>Phenobarbital for Acute Alcohol Withdrawal</brief_title>
  <official_title>Phenobarbital Versus Placebo for Acute Alcohol Withdrawal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonathan Rosenson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alameda County Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Alameda County Medical Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board ACMC (for Oversight Authority)</authority>
    <authority>**Note: This study was approved by the ACMC Ethics committee in conjunction with the ACMC IRB.</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intravenous phenobarbital in combination with a symptom-guided standardized lorazepam-based
      alcohol withdrawal protocol will be associated with decreased need for ICU admission,
      continuous lorazepam infusion and will not be associated with increased adverse events.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Patients Requiring Continuous Lorazepam Infusion</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>All study patients are placed on the standardized institutional alcohol withdrawal protocol and receive boluses of lorazepam (1, 2 or 4 mg IV) based on their acute alcohol withdrawal score (AAWS), adminstered serially up to every 15 minutes. Patients who are refractory to the maximum dose of lorazepam allowed by the protocol (up to 4mg lorazepam IV q 15 mins)are placed on a continuous IV lorazepam infusion (or &quot;lorazepam drip&quot;). Thus, continuous lorazepam infusion is a &quot;yes or no&quot; variable (i.e. continuous infusion, or not).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Patients Requiring ICU Admission</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>admission to intensive care unit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Lorazepam Required Per Patient Per Admission</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>How much total lorazepam did each study patient receive from inital presentation in the Emergency Department through their discharge from the hospital, in milligrams.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>hospital LOS, per patient, in hours from admission to discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Requiring Endotracheal Intubation as a Measure of Safety and Tolerability</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The outome answeres the question &quot;Did the study patient require endotracheal intubation, or not&quot;. This outcome investigates if the phenobarbital intervention is associted with increased incidence of respiratory depression and subsequent increased need for intubation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Requiring a Bedside Sitter as a Measure of Safety and Tolerability</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Did the study patient require a Licensed Vocational Nurse (LVN) or other hospital staff to serve as a &quot;bedside sitter&quot; to observe the patient and provide additional safety supervision during any portion of their hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Study Patients With Seizure as a Measure of Safety and Tolerability</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Did the study patient have a witnessed seizure during their hospitaliztion (yes/no).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Study Patients With Mortality as a Measure of Safety and Tolerability</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>mortality in study patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Alcohol Withdrawal</condition>
  <arm_group>
    <arm_group_label>Phenobarbital group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg/kg IV phenobarbital in 100 ml saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 ml saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10 mg/kg IV phenobarbital in 100 ml saline</intervention_name>
    <description>10 mg/kg IV phenobarbital in 100 ml saline</description>
    <arm_group_label>Phenobarbital group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>100 m l saline</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Need for admission to hospital for acute alcohol withdrawal

        Exclusion Criteria:

          -  allergy to phenobarbital, lorazepam, age&lt;18 or &gt;65
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alameda County Medical Center</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <lastchanged_date>March 7, 2012</lastchanged_date>
  <firstreceived_date>August 17, 2010</firstreceived_date>
  <firstreceived_results_date>February 18, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Alameda County Medical Center</investigator_affiliation>
    <investigator_full_name>Jonathan Rosenson</investigator_full_name>
    <investigator_title>Jonathan Rosenson MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Phenobarbital</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Phenobarbital Group</title>
          <description>10 mg/kg IV phenobarbital in 100 ml saline</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>100 ml saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phenobarbital Group</title>
          <description>10 mg/kg IV phenobarbital in 100 ml saline</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>100 ml saline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="51"/>
                <measurement group_id="B2" value="51"/>
                <measurement group_id="B3" value="102"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="51"/>
                <measurement group_id="B2" value="51"/>
                <measurement group_id="B3" value="102"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="46" spread="12"/>
                <measurement group_id="B2" value="48" spread="17"/>
                <measurement group_id="B3" value="47" spread="14"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="46"/>
                <measurement group_id="B2" value="45"/>
                <measurement group_id="B3" value="91"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="51"/>
                <measurement group_id="B2" value="51"/>
                <measurement group_id="B3" value="102"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Requiring Continuous Lorazepam Infusion</title>
        <description>All study patients are placed on the standardized institutional alcohol withdrawal protocol and receive boluses of lorazepam (1, 2 or 4 mg IV) based on their acute alcohol withdrawal score (AAWS), adminstered serially up to every 15 minutes. Patients who are refractory to the maximum dose of lorazepam allowed by the protocol (up to 4mg lorazepam IV q 15 mins)are placed on a continuous IV lorazepam infusion (or &quot;lorazepam drip&quot;). Thus, continuous lorazepam infusion is a &quot;yes or no&quot; variable (i.e. continuous infusion, or not).</description>
        <time_frame>1 year</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Phenobarbital Group</title>
            <description>10 mg/kg IV phenobarbital in 100 ml saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>100 ml saline</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="51"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Patients Requiring Continuous Lorazepam Infusion</title>
            <description>All study patients are placed on the standardized institutional alcohol withdrawal protocol and receive boluses of lorazepam (1, 2 or 4 mg IV) based on their acute alcohol withdrawal score (AAWS), adminstered serially up to every 15 minutes. Patients who are refractory to the maximum dose of lorazepam allowed by the protocol (up to 4mg lorazepam IV q 15 mins)are placed on a continuous IV lorazepam infusion (or &quot;lorazepam drip&quot;). Thus, continuous lorazepam infusion is a &quot;yes or no&quot; variable (i.e. continuous infusion, or not).</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Requiring ICU Admission</title>
        <description>admission to intensive care unit</description>
        <time_frame>1 year</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Phenobarbital Group</title>
            <description>10 mg/kg IV phenobarbital in 100 ml saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>100 ml saline</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="51"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Patients Requiring ICU Admission</title>
            <description>admission to intensive care unit</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8" lower_limit="4" upper_limit="32"/>
                  <measurement group_id="O2" value="25" lower_limit="4" upper_limit="32"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4</ci_lower_limit>
            <ci_upper_limit>32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Lorazepam Required Per Patient Per Admission</title>
        <description>How much total lorazepam did each study patient receive from inital presentation in the Emergency Department through their discharge from the hospital, in milligrams.</description>
        <time_frame>1 year</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Phenobarbital Group</title>
            <description>10 mg/kg IV phenobarbital in 100 ml saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>100 ml saline</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="51"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Total Lorazepam Required Per Patient Per Admission</title>
            <description>How much total lorazepam did each study patient receive from inital presentation in the Emergency Department through their discharge from the hospital, in milligrams.</description>
            <units>milligrams</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26" spread="45" lower_limit="7" upper_limit="49"/>
                  <measurement group_id="O2" value="49" spread="37" lower_limit="7" upper_limit="49"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4</ci_lower_limit>
            <ci_upper_limit>49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Stay</title>
        <description>hospital LOS, per patient, in hours from admission to discharge</description>
        <time_frame>1 year</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Phenobarbital Group</title>
            <description>10 mg/kg IV phenobarbital in 100 ml saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>100 ml saline</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="51"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Length of Stay</title>
            <description>hospital LOS, per patient, in hours from admission to discharge</description>
            <units>hours</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="76" lower_limit="54" upper_limit="114"/>
                  <measurement group_id="O2" value="118" lower_limit="47" upper_limit="190"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4</ci_lower_limit>
            <ci_upper_limit>82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Requiring Endotracheal Intubation as a Measure of Safety and Tolerability</title>
        <description>The outome answeres the question &quot;Did the study patient require endotracheal intubation, or not&quot;. This outcome investigates if the phenobarbital intervention is associted with increased incidence of respiratory depression and subsequent increased need for intubation.</description>
        <time_frame>1 year</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Phenobarbital Group</title>
            <description>10 mg/kg IV phenobarbital in 100 ml saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>100 ml saline</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="51"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Patients Requiring Endotracheal Intubation as a Measure of Safety and Tolerability</title>
            <description>The outome answeres the question &quot;Did the study patient require endotracheal intubation, or not&quot;. This outcome investigates if the phenobarbital intervention is associted with increased incidence of respiratory depression and subsequent increased need for intubation.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Requiring a Bedside Sitter as a Measure of Safety and Tolerability</title>
        <description>Did the study patient require a Licensed Vocational Nurse (LVN) or other hospital staff to serve as a &quot;bedside sitter&quot; to observe the patient and provide additional safety supervision during any portion of their hospitalization.</description>
        <time_frame>1 year</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Phenobarbital Group</title>
            <description>10 mg/kg IV phenobarbital in 100 ml saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>100 ml saline</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="51"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Patients Requiring a Bedside Sitter as a Measure of Safety and Tolerability</title>
            <description>Did the study patient require a Licensed Vocational Nurse (LVN) or other hospital staff to serve as a &quot;bedside sitter&quot; to observe the patient and provide additional safety supervision during any portion of their hospitalization.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28" lower_limit="-11" upper_limit="23"/>
                  <measurement group_id="O2" value="22" lower_limit="-11" upper_limit="23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11</ci_lower_limit>
            <ci_upper_limit>23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Study Patients With Seizure as a Measure of Safety and Tolerability</title>
        <description>Did the study patient have a witnessed seizure during their hospitaliztion (yes/no).</description>
        <time_frame>1 year</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Phenobarbital Group</title>
            <description>10 mg/kg IV phenobarbital in 100 ml saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>100 ml saline</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="51"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Study Patients With Seizure as a Measure of Safety and Tolerability</title>
            <description>Did the study patient have a witnessed seizure during their hospitaliztion (yes/no).</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Study Patients With Mortality as a Measure of Safety and Tolerability</title>
        <description>mortality in study patients</description>
        <time_frame>1 year</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Phenobarbital Group</title>
            <description>10 mg/kg IV phenobarbital in 100 ml saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>100 ml saline</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="51"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Study Patients With Mortality as a Measure of Safety and Tolerability</title>
            <description>mortality in study patients</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jonathan Rosenson MD</name_or_title>
      <organization>Alameda County Medical Center</organization>
      <phone>510-407-6743</phone>
      <email>jonrosenson@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
